

Florina 01.01.2024

Dear Colleague,

We report the results from the analysis on patient (**ID-XXXX**) **XXXXXX** . The sample we received for analysis was a **XX ml** of whole blood that contained EDTA-Ca as anti-coagulant and packed with an ice pack. Upon arrival there were performed:

- Malignant cell isolation and then positive and negative selection using multiple cell markers.
- DNA extraction from the above cells and evaluation of the above with molecular-based assays as well with spectrophotometry.
- CGH experiments using commercial reference genomic DNA samples.

The results after process are presented below:

Chromosome/ Size	Start- Stop Position (bp)	Genes	Outcome
AMP 11p15.4/ 753 Kb	5529738- 6282871	UBQLN3 (OMIM), TRIM6 (OMIM), TRIM34 (OMIM), TRIM5 (OMIM), TRIM22 (OMIM), FAM160A2 (OMIM), CNGA4 (OMIM), CCKBR (OMIM), UBQLNL, OLFM5P, OR52H1, OR52B6, TRIM6-TRIM34, OR56B1, OR52N4, OR52N5, OR52N1, OR52N2, OR52E6, OR52E8, OR52E4, OR52E5, OR56A3, OR56A5, OR52L1, OR56A4, OR56A1, OR56B4, OR52B2, OR52W1, C11orf42	PATHOGENIC TRIM Family → Contribute to tumorigenesis, cancer development and drug resistance TRIM6 → Overexpressed in colorectal and breast cancer TRIM22 → Downregulated in gastric cancer. Overexpressed in glioblastoma.



*Research Genetic Cancer Centre S.A.
Industrial Area of Florina, GR- 53100, Florina, Greece*

Appendix:

DEL: Deletion

AMP: Amplification

CNP: Copy Number Polymorphic-Normal variation in DNA which are common and widely distributed in human genome

Conclusion: The aberrations that have been detected are more compatible with breast carcinoma and less for colorectal.

Sincerely,

Panagiotis Apostolou
Molecular Biologist

Ioannis Papatotiriou MD., PhD
Head of molecular medicine dpt. of
R.G.C.C.-RESEARCH GENETIC
CANCER CENTRE S.A.